Neurodegenerative Diseases Therapeutics Market 2024-2028: Size and Lack of disease-modifying therapies; growth driven by the Indication, Some of key Companies Positioned Strategically

The neurodegenerative diseases therapeutics market size by Indication (Multiple sclerosis, Alzheimers disease, Parkinsons disease, Huntingtons disease, and Others) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 21290 million. The market is expected to grow at a CAGR of   8.51% between 2024 and 2028.

• The global neurodegenerative diseases therapeutics market faces a significant challenge due to the rising prevalence of conditions like Alzheimer's disease, which doubles in frequency every five years after the age of 65 and affects up to 50% of those over 85. While there are approved symptomatic treatments for diseases such as Parkinson's and Alzheimer's, there are currently no disease-modifying therapies for neurodegenerative diseases like Huntington's, which is caused by a mutation in the huntingtin gene. The urgent need for disease-modifying therapies is imperative to address the unmet medical needs and positively impact the lives of millions of patients worldwide.
• The Neurodegenerative Diseases Therapeutics Market represents a significant business opportunity for pharmaceutical companies, with a growing demand for innovative treatments. This market is driven by the increasing prevalence of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease. Companies are investing heavily in research and development to bring novel therapies to market, focusing on disease-modifying treatments and symptomatic relief. The market is expected to grow at a robust rate, offering substantial returns for investors.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• AB Science SA
• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Biogen Inc.
• F. Hoffmann La Roche Ltd.
• H Lundbeck AS
• Mitsubishi Chemical Corp.
• Novartis AG
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/